Skip to ContentSkip to Navigation
founded in 1614  -  top 100 university
About us Practical matters How to find us D. (Dick) de Zeeuw
University Medical Center Groningen

D. (Dick) de Zeeuw

Professor;Depart of Clinical Pharmacy and Pharmacology
Profile picture of D. (Dick) de Zeeuw
Telephone:
E-mail:
d.de.zeeuw umcg.nl

Publications

Cumulative Effects of Vicadrostat and Empagliflozin on Albuminuria in CKD

Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE

Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression

Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial

Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease A Systematic Review and Retrospective Individual Participant–Level Meta-analysis of Clinical Trials

A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope

Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes

Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial

Methods Article for a Study Protocol: Study Design and Baseline Characteristics for Aldosterone Synthase Inhibition in Chronic Kidney Disease

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

Press/media

‘Drug rediscovery vraagt bevlogen onderzoekers met creatieve invallen’

Sustainable Development Goals

SDG 3 - Good Health and Well-beingSDG 5 - Gender EqualitySDG 9 - Industry, Innovation, and InfrastructureSDG 10 - Reduced InequalitiesSDG 17 - Partnerships for the Goals

More information about the Sustainable Development Goals.